In this article, Jim Robertson at Wynne Jones IP discusses how uncertainty surrounding a potential no-deal Brexit has created a deep chasm in opinion in relation to the future of the UK’s lucrative pharmaceutical industry and about the sector’s ability to function effectively post-Brexit.